Experienced in Carney Complex

Dr. Laura B. Huffman

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Aspirus Medical Group Inc
2720 Plaza Dr, Suite 2100, 
Wausau, WI 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Carney Complex
Aspirus Medical Group Inc
2720 Plaza Dr, Suite 2100, 
Wausau, WI 
OverviewInsuranceLocationsClinical Research

Overview

Laura Huffman is a Gynecologic Oncologist and an Oncologist in Wausau, Wisconsin. Dr. Huffman and is rated as an Experienced provider by MediFind in the treatment of Carney Complex. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Vaginal Cancer, Oophorectomy, and Salpingo-Oophorectomy. Dr. Huffman is currently accepting new patients.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in AR
Hospital Affiliations
University Of Wi Hospitals & Clinics Authority
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Quartz
  • HMO
  • POS
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
View 2 Less Insurance Carriers -

Locations

ASPIRUS MEDICAL GROUP INC
2720 Plaza Dr, Suite 2100, Wausau, WI 54401
Other Locations
UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION INC
600 Highland Ave, Madison, WI 53792

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: March 19, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Recruiting
Publish Date: May 02, 2024
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Other, Procedure
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
View 2 Less Clinical Trial

10 Total Publications

Clinical cell-surface targets in metastatic and primary solid cancers.
Clinical cell-surface targets in metastatic and primary solid cancers.
Journal: JCI insight
Published: September 24, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huffman's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile